13,644 Shares in Moderna, Inc. (NASDAQ:MRNA) Bought by Diversified Trust Co

Diversified Trust Co purchased a new stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 13,644 shares of the company's stock, valued at approximately $387,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Sentry Investment Management LLC bought a new position in shares of Moderna during the 1st quarter valued at about $31,000. Crowley Wealth Management Inc. purchased a new stake in Moderna in the 4th quarter worth approximately $41,000. Itau Unibanco Holding S.A. lifted its holdings in Moderna by 51.2% in the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock worth $42,000 after buying an additional 343 shares during the period. Vega Investment Solutions purchased a new stake in Moderna in the 4th quarter worth approximately $45,000. Finally, Versant Capital Management Inc lifted its stake in shares of Moderna by 408.9% in the 1st quarter. Versant Capital Management Inc now owns 1,593 shares of the company's stock valued at $45,000 after purchasing an additional 1,280 shares during the period. Hedge funds and other institutional investors own 75.33% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Royal Bank Of Canada lowered their target price on Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a research note on Friday, May 2nd. Evercore ISI lowered their target price on Moderna from $50.00 to $32.00 and set an "in-line" rating for the company in a research note on Friday, May 2nd. William Blair restated a "market perform" rating on shares of Moderna in a research note on Monday, June 2nd. Citigroup assumed coverage on Moderna in a research note on Thursday, March 13th. They issued a "neutral" rating and a $40.00 target price for the company. Finally, Morgan Stanley lowered their target price on Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a research note on Wednesday, April 9th. Four research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Moderna currently has an average rating of "Hold" and a consensus target price of $46.61.

Moderna Stock Up 5.5%

Shares of Moderna stock traded up $1.59 on Wednesday, reaching $30.28. The company's stock had a trading volume of 14,693,915 shares, compared to its average volume of 8,672,848. The firm's fifty day simple moving average is $26.59 and its two-hundred day simple moving average is $31.60. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $129.39.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, topping analysts' consensus estimates of ($2.92) by $0.40. The business had revenue of $108.00 million during the quarter, compared to analyst estimates of $130.35 million. Moderna had a negative return on equity of 28.69% and a negative net margin of 105.67%. The company's quarterly revenue was down 35.3% compared to the same quarter last year. During the same quarter last year, the company earned ($3.07) EPS. Equities analysts predict that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.